Results 171 to 180 of about 64,427 (282)

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone. [PDF]

Cells, 2022
Macedo TR, de Queiroz GF, Casagrande TAC, Alexandre PA, Brandão PE, Fukumasu H, Melo SR, Dagli MLZ, Pinto ACBCF, Matera JM.   +9 more
europepmc   +1 more source

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy [PDF]

, 2003
Animesh Pardanani, Rhett P. Ketterling, Stephanie R. Brockman, Heather C. Flynn, Sarah F. Paternoster, Brandon M. Shearer, Terra L. Reeder, Chin‐Yang Li, Nicholas C.P. Cross, Jan Cools, D. Gary Gilliland, Gordon W. Dewald, Ayalew Tefferi   +12 more
openalex   +1 more source

Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor

Clinical Cancer Research, 2016
Phillip Zook, H. Pathak, M. Belinsky, Lawrence Gersz, K. Devarajan, Yan Zhou, A. Godwin, M. von Mehren, L. Rink   +8 more
semanticscholar   +1 more source

In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery. [PDF]

Int J Nanomedicine, 2021
Xu H, Ji H, Li Z, Qiao W, Wang C, Tang J.   +5 more
europepmc   +1 more source

The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia

Медицинский вестник Юга России, 2010
Imatinib mesylate is a potent and high selective inhibitor of Bcr-Abl tyrosine kinase, which is established now as the standard of Philadelphia chromosome positive (Ph) chronic myeloid leukemia (CML) treatment.
S. I. Kutsev, S. V. Mordanov, A. N. Zeltser, O. S. Oxenjuk, O. A. Ustaeva, T. I. Kungurova, E. V. Burnasheva, E. Grankina, Yu. V. Shatokhin   +8 more
doaj  

Imatinib Mesylate-Induced Acquired Dermal Melanocytosis and Acquired Bilateral Nevus of Ota-Like Macules. [PDF]

Ann Dermatol, 2021
Jang JW, Song CH, Jung YJ, Cheon DU, Koh WS, Ro YS, Ko JY.   +6 more
europepmc   +1 more source

Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance

Revista Brasileira de Hematologia e Hemoterapia, 2013
OBJECTIVE: The goal of this study was to monitor imatinib mesylate therapeutically in the Tumor Biology Laboratory, Department of Hematology and Hemotherapy, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (USP).
Vinícius Marcondes Rezende, Ariane Julio Rivellis, Melissa Medrano Gomes, Felipe Augusto Dörr, Mafalda Megumi Yoshinaga Novaes, Luciana Nardinelli, Ariel Lais de Lima Costa, Dalton de Alencar Fisher Chamone, Israel Bendit   +8 more
doaj  

In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models. [PDF]

Transl Vis Sci Technol, 2021
Baek YY, Sung B, Choi JS, Go HK, Kim DH, Hyon JY, You JC.   +6 more
europepmc   +1 more source

Successful treatment of metastatic dermatofibrosarcoma protuberans of the breast to the lungs with imatinib mesylate: a case report. [PDF]

Ecancermedicalscience
Kpatsi S, Daniels J, Kyei KA, Vanderpuye V.   +3 more
europepmc   +1 more source

Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol. [PDF]

Medicine (Baltimore), 2021
Hirai I, Tanese K, Fukuda K, Fusumae T, Nakamura Y, Sato Y, Amagai M, Funakoshi T.   +7 more
europepmc   +1 more source